In a report published Monday, Loewen Ondaatje McCutcheon reiterated its Buy rating and $7.50 price target on BioMimetic Therapeutics BMTI.
Loewen Ondaatje McCutcheon noted, “Overall, our views are mixed on the acquisition of BMTI by Wright Medical. On the positive side, the valuation is roughly in line with our base case outlook for BMTI shares if Augment were approved in 2013 (i.e., EV/share of approximately $8.40).”
BioMimetic Therapeutics closed on Friday at $4.15.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in